¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lymphocyte microcytotoxicity assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤(¹ý), ¿ëÇ÷ÇöóÅ©ÃøÁ¤(¹ý)
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤(¹ý), ¸é¿ªÇü±¤°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤, ¸²ÇÁ±¸¼¼Æ÷µ¶¼º°Ë»ç
  • plaque assay
    ÆÇÃøÁ¤(¹ý), ÇöóÅ©ÃøÁ¤(¹ý)
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    Ãʰú»êÈ­¹°ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • focus assay
    ¹ÙÀÌ·¯½ºÆ÷Ä¿½ºÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁýÃøÁ¤(¹ý)
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ©ÃøÁ¤¹ý
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    °ú»êÈ­¹°ÃøÁ¤
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibiotic assay
    Ç×»ý¹°Áú ¹ÙÀÌ¿ÀÆò°¡.
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigenic assay
    Ç׿ø¼ººÐ¼®
  • antimicobial assay
    Ç×±ÕÁ¦ÃøÁ¤
  • growth hormone assay
    ¼ºÀåÈ£¸£¸óÃøÁ¤
  • hemizona assay (index)
    ¹ÝÅõ¸í´ë ÃøÁ¤(ÁöÇ¥)
  • hemolytic plaque assay
    ¿ëÇ÷¹Ý ÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ© ÃøÁ¤¹ý
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • immunoconcentration assay
    ¸é¿ª³óÃàÃøÁ¤<--Á¤·®
  • immunoenzymometric assay
    ¸é¿ªÈ¿¼Ò°èÃø<--°è·®>ºÐ¼®
  • immunofluorescence assay
    ¸é¿ªÇü±¤°Ë»ç
  • immunometric assay
    ¸é¿ª°è·®<--°èÃø>°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • plaque assay
    ÇöóÅ© ÃøÁ¤¹ý
  • plaque assay, hemolytic
    ¿ëÇ÷¼º ÇöóÅ© Çü¼º½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸À¯·¡ È­ÇÐÁÖ¼ºÀÎÀÚ
  • lymphocyte-detected membrane antigen
    ¸²ÇÁ±¸-°ËÃâ ¼¼Æ÷¸·Ç׿ø
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(ñ顭Ϲ).
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(Ì¡?Ë´).
  • medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç(̴̰?Ë´ËÑËâ).
  • mixed lymphocyte culture
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç(¡­ûèùêÏ¹ÛÆå×).
  • mixed lymphocyte culture(MLC)
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸ È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte response(MLR)
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ӤϹ¡­Ï¹Ýï).
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ËÀË´?Ë´ËÓ).
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ELISA Enzyme-Linked Immuno-Sorbent Assay; È¿¼Ò ¸é¿ª¹ý
IFA Immuno-Fluorescence Antibody Test(= Assay)
IRMA   1) Intra-Retinal Microvascular Abnormalities
  2) Immuno-Radio-Metric Assay...
MHA-TP Micro-Hemagglutination Assay for antibodies to Treponema Pallidum
RIA Radio-Immuno-Assay; ¹æ»ç ¸é¿ª¹ý
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EMSA Electrophoretic Mobility Shift Assay
EMSA Electrophoretic gel mobility shift assay
EIA Enzyme Immune Assay
EIA Enzyme Immunosorbent Assay
ELLA Enzyme Linked Lectin Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • micrologica assay
    ¹Ì»ý¹°ÇÐÀû Á¤·®¹ý
  • radioreceptor assay
    ¹æ»ç¼± ¼ö¿ëü ÃøÁ¤¹ý
    ÀÏÁ¾ÀÇ ¹æ»ç Ç¥Áö °ËÁ¤¹ýÀ¸·Î¼­, Á¶Á÷ Ç¥º» ³»¿¡ Àִ ȣ¸£¸ó¿¡ ´ëÇØ Ư¼öÇÑ ¼¼Æ÷ ¼ö¿ëüÀÇ ³óµµ¸¦ ¹æ»ç Ç¥ÁöÇÑ È£¸£¸óÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÏ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
t-lymphocyte subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
(12 Dec 1998)
transformed lymphocyte See: lymphocyte transformation.
(05 Mar 2000)
epitopes, b-lymphocyte Antigenic determinants recognised and bound by the B-cell receptor. Epitopes recognised by the B-cell receptor are located on the surface of the antigen.
(12 Dec 1998)
epitopes, t-lymphocyte Antigenic determinants recognised and bound by the T-cell receptor. Epitopes recognised by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
(12 Dec 1998)
tumour-infiltrating lymphocyte <haematology, oncology> Special cancer-fighting cells of the immune system found in tumours. In a type of experimental therapy, scientists harvest these cells from the tumour, grow them in a laboratory and then return them to the patient with the hope of the cells destroying the tumour.
These cells can be collected from the site of a tumour and exposed to IL-2 in vitro. When these cells are injected back into the tumour bearing host, they will specifically kill the tumour from which they originated.
(05 Mar 2000)
lymphocyte <haematology> White cell of the blood that are derived from stem cells of the lymphoid series.
Two main classes are recognised, T and B lymphocytes, the latter responsible (when activated) for production of antibody, the former subdivided into subsets (helper, suppressor, cytotoxic T-cells) and responsible both for cell-mediated immunity and for stimulating B-cells.
(18 Nov 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte cooperation T-cell enhancement of the B-cell response to thymic-dependent antigens.
(12 Dec 1998)
lymphocyte count A count of the number of lymphocytes in the blood.
(12 Dec 1998)
lymphocyte depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
(12 Dec 1998)
lymphocyte function associated antigen A member of the integrin family that is expressed on all leukocytes and binds to ICAM-1 and ICAM-2 on a variety of cells.
(05 Mar 2000)
lymphocyte function-associated antigen-1 A heterodimer molecule widely expressed on cells of haematopoietic origin. Cd11a antigen comprises the alpha chain and the CD18 antigen (antigens, CD18) the beta chain. Lfa-1 is a major receptor of T-cells, B-cells, and granulocytes. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes. Intracellular adhesion molecule-1 (icam-1) has been defined as a ligand for lfa-1.
(12 Dec 1998)
lymphocyte-oriented kinase <enzyme> An ste20-like protein kinase; genbank d89728
Registry number: EC 2.7.10.-
Synonym: lok gene product
(26 Jun 1999)
lymphocyte specific protein tyrosine kinase p56(lck) <enzyme> This enzyme is a lymphoid specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the il-2 receptor, and is thought to be involved in the earliest steps of tcr-mediated T-cell activation.
Registry number: EC 2.7.11.-
(12 Dec 1998)
lymphocyte subsets A classification of lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á